var data={"title":"Colchicine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Colchicine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5940?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">see &quot;Colchicine: Drug information&quot;</a> and <a href=\"topic.htm?path=colchicine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Colchicine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8108144\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Colcrys;</li>\n      <li>Mitigare</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13869718\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Jamp-Colchicine;</li>\n      <li>PMS-Colchicine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046565\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antigout Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046556\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">see &quot;Colchicine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Familial Mediterranean Fever (FMF)</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Colcrys:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to 6 years: Oral: 0.3 to 1.8 mg/day in 1 to 2 divided doses; titrate by increasing or decreasing dose in 0.3 mg/day increments based on efficacy or adverse effects; maximum dose: 2.4 mg/<b>day</b>; some guidelines recommend a lower maximum daily dose (2 mg/<b>day</b>) (EULAR [Ozen 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;6 to 12 years: Oral: 0.9 to 1.8 mg/day in 1 to 2 divided doses; titrate by increasing or decreasing dose in 0.3 mg/day increments based on efficacy or adverse effects; maximum dose: 2.4 mg/<b>day</b>; some guidelines recommend a lower maximum daily dose (2 mg/<b>day</b>) (EULAR [Ozen 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;12 years and Adolescents: Oral: 1.2 to 2.4 mg/day in 1 to 2 divided doses; titrate by increasing or decreasing dose in 0.3 mg/day increments based on efficacy or adverse effects; maximum dose: 2.4 mg/<b>day</b>; some guidelines recommend a lower maximum daily dose (2 mg/<b>day</b>) (EULAR [Ozen 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gout:</b> Colcrys: Adolescents &gt;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flare treatment: Initial: Oral: 1.2 mg at the first sign of flare, followed in 1 hour with a single dose of 0.6 mg (maximum dose: 1.8 mg over 1 hour). Patients receiving prophylaxis treatment may receive treatment dosing; wait 12 hours before resuming prophylactic dose; wait at least 3 days before repeating treatment dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: Oral: 0.6 mg once or twice daily; maximum daily dose: 1.2 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant therapy with CYP3A4 or P-gp inhibitors:</b> Dosage adjustment is required in patients receiving CYP3A4 or P-gp inhibitors up to 14 days prior to initiation of colchicine. <b>Note: </b>Treatment of gout flare with colchicine is not recommended in patients receiving prophylactic colchicine and CYP3A4 inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coadministration of <b>strong</b> CYP3A4 inhibitor (eg, atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FMF: Children &ge;4 years and Adolescents: Oral: Reduce maximum dose to 0.6 mg once daily <b>or</b> 0.3 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout prophylaxis: Adolescents &gt;16 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If original dose is 0.6 mg once daily, adjust dose to 0.3 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout flare treatment: Adolescents &gt;16 years: Oral: Initial: 0.6 mg, followed in 1 hour by a single dose of 0.3 mg; wait at least 3 days to repeat</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coadministration of <b>moderate</b> CYP3A4 inhibitor (eg, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, verapamil):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FMF: Children &ge;4 years and Adolescents: Oral: Reduce maximum dose to 1.2 mg once daily <b>or</b> 0.6 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout prophylaxis: Adolescents &gt;16 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg twice daily <b>or </b>0.6 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If original dose is 0.6 mg once daily, adjust dose to 0.3 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout flare treatment: Adolescents &gt;16 years: Oral: 1.2 mg as a single dose; wait at least 3 days to repeat days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coadministration of P-gp inhibitor (eg, cyclosporine, ranolazine):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FMF: Children &ge;4 years and Adolescents: Oral: Reduce maximum dose to 0.6 mg once daily <b>or</b> 0.3 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout prophylaxis: Adolescents &gt;16 years: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If original dose is 0.6 mg once daily, adjust dose to 0.3 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout flare treatment: Adolescents &gt;16 years: Oral: Initial: 0.6 mg as a single dose; wait at least 3 days to repeat</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Concurrent use of colchicine and P-gp or strong CYP3A4 inhibitors is <b>contraindicated</b> in renal impairment. Use of colchicine to treat gout flares is not recommended in patients with renal impairment receiving prophylactic colchicine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children (Kallinich, 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate impairment (CrCl 10-50 mL/minute): Consider dose reduction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (CrCl &lt;10 mL/minute): Reduce dose by 50% or consider discontinuation of therapy; maximum dose: 1 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">FMF:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30-80 mL/minute: Monitor closely for adverse effects; dose adjustment may be necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Initial dose: 0.3 mg/day; use caution if dose titrated; monitor for adverse effects</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dialysis: Nondialyzable: Initial dose: 0.3 mg/day; dosing can be increased with close monitoring; monitor for adverse effects. Not removed by dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gout prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30-80 mL/minute: Dosage adjustment not required; monitor closely for adverse effects</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Initial dose: 0.3 mg/day; use caution if dose titrated; monitor for adverse effects</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dialysis: Nondialyzable: 0.3 mg twice weekly; monitor closely for adverse effects</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gout flare treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30-80 mL/minute: Dosage adjustment not required; monitor closely for adverse effects</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Dosage adjustment may be considered; treatment course should not be repeated more frequently than every 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dialysis: Nondialyzable: 0.6 mg as a single dose; wait at least 14 days to repeat</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154279\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mitigare: 0.6 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Colcrys: 0.6 mg [scored; contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.6 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154263\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097684\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Colcrys:<a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022352s022lbl.pdf#page=24&amp;token=Y8XLqls8DA4CCB6ceSXpIei6XWhkpfA01eNqfOfVVV9WexeF5p9sIfiC/qWA+ryE+UCh5jFpI9ErmbfzshRcti0EYVmeemrv4TAm8d1K5V5T3RiqybbCbb6AvDwVcVaC&amp;TOPIC_ID=13179\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022352s022lbl.pdf#page=24</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Mitigare:<a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM417495.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giuIJcKlHDBxiC41k8IE7QUA==&amp;TOPIC_ID=13179\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM417495.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046568\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer without regard to meals and maintain adequate fluid intake; avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104450\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154297\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light and moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046567\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of familial Mediterranean fever (FMF) (Colcrys: FDA approved in ages &ge;4 years and adults); prevention and treatment of acute gout flares (Colcrys: FDA approved in ages &gt;16 years and adults; Mitigare: FDA approved in adults). <b>Note:</b> Approved ages and indications for generic products may vary; consult labeling for specific information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154346\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Colchicine may be confused with Cortrosyn</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154343\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Gout</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal pain, diarrhea, gastrointestinal disease, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pharyngolaryngeal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Alopecia, bone marrow depression, dermatitis, disseminated intravascular coagulation, dysgeusia (Syed 2016), hepatotoxicity, hypersensitivity reaction, increased creatine phosphokinase, lactose intolerance, myalgia, myasthenia, oligospermia, purpura, rhabdomyolysis, toxic neuromuscular disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154285\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Concomitant use of a P-glycoprotein (P-gp) or strong CYP3A4 inhibitor in presence of renal or hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitigare: Patients with both renal and hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to colchicine; serious gastrointestinal, hepatic, renal, and cardiac disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154267\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: Myelosuppression (eg, thrombocytopenia, leukopenia, granulocytopenia, pancytopenia) and aplastic anemia have been reported in patients receiving therapeutic doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal symptoms: Dosage reduction is recommended in patients who develop gastrointestinal symptoms (anorexia, diarrhea, nausea, vomiting) related to drug therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular toxicity: Myotoxicity (including rhabdomyolysis) has been reported in patients receiving therapeutic doses; patients with renal dysfunction and elderly patients are at increased risk. Concomitant use of cyclosporine, diltiazem, verapamil, fibrates, and statins may increase the risk of myopathy. Symptoms typically resolve within 1 week to several months of colchicine discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Clearance is decreased in hepatic impairment; monitor closely for adverse effects/toxicity. Dosage adjustments may be considered depending on degree of impairment or indication, and may be affected by the use of concurrent medication (CYP3A4 or P-gp inhibitors). Concurrent use of P-gp or strong CYP3A4 inhibitors is contraindicated in hepatic impairment. Fatal toxicity has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Clearance is decreased in renal impairment; monitor closely for adverse effects/toxicity. Dosage adjustments may be required depending on degree of impairment or indication, and may be affected by the use of concurrent medication (CYP3A4 or P-gp inhibitors). Concurrent use of P-gp or strong CYP3A4 inhibitors is contraindicated in renal impairment. Fatal toxicity has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; literature suggests dosage adjustments should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Colchicine is not an analgesic and should not be used to treat pain from other causes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fatal overdose: Accidental and intentional fatal overdoses have been reported. Dosage associated with fatal toxicity is variable (eg, wide dosage range).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154332\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154272\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13179&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Colchicine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Colchicine may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanocobalamin: Colchicine may decrease the serum concentration of Cyanocobalamin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: May increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: May enhance the myopathic (rhabdomyolysis) effect of Colchicine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are receiving ritonavir-boosted fosamprenavir.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Colchicine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Colchicine may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Colchicine may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, colchicine may decrease absorption of cyanocobalamin (vitamin B12). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Colchicine may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, colchicine may decrease the serum concentration of Cyanocobalamin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): Colchicine may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, colchicine may decrease absorption of cyanocobalamin (vitamin B12). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): May increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Colchicine. Management: Colchicine should not be used with telaprevir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with telaprevir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Colchicine. Management: Colchicine should not be used with tipranavir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with tipranavir.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154299\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase colchicine serum concentrations. Management: Administer orally with water and maintain adequate fluid intake. Dose adjustment may be required based on indication if ingesting grapefruit juice. Avoid grapefruit juice with hepatic or renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154275\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10923644\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Colchicine crosses the human placenta. Use during pregnancy in the treatment of familial Mediterranean fever has not shown an increase in miscarriage, stillbirth, or teratogenic effects (limited data).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046564\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, urinalysis, and renal and hepatic function tests</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FMF: CRP, serum amyloid A (SAA) protein (every 3 months during dose escalation), creatinine phosphokinase (CPK), proteinuria, GFR (EULAR [Ozen 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154266\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Disrupts cytoskeletal functions by inhibiting &beta;-tubulin polymerization into microtubules, preventing activation, degranulation, and migration of neutrophils associated with mediating some gout symptoms. In familial Mediterranean fever, may interfere with intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediate activation of interleukin-1&beta;.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154284\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: Pain relief: ~18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Concentrates in leukocytes, kidney, spleen, and liver; does not distribute in heart, skeletal muscle, and brain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: 5 to 8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~39%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4; 3 metabolites (2 primary, 1 minor)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 27 to 31 hours (multiple oral doses; young, healthy volunteers)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 0.5 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (40% to 65% as unchanged drug); enterohepatic recirculation and biliary excretion also possible</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154287\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Colchicine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $653.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mitigare Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $718.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Colchicine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $673.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Colcrys Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (30): $244.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154289\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Artrichine (EC);</li>\n      <li>Calchicine Houde (PY);</li>\n      <li>Cholchicin &rdquo;Agepha&rdquo; (AT);</li>\n      <li>Cochic (TH);</li>\n      <li>Cocine (TW);</li>\n      <li>Colchicin Agepha (AT);</li>\n      <li>Colchicina Lirca (IT);</li>\n      <li>Colchicina Phoenix (AR);</li>\n      <li>Colchicine (IL);</li>\n      <li>Colchicine capsules (NL);</li>\n      <li>Colchicine Houde (AR, BE, FR, LU, PT);</li>\n      <li>Colchicum-Dispert (BG, DE, HU, PL, TR);</li>\n      <li>Colchifar (VN);</li>\n      <li>Colchily (TH);</li>\n      <li>Colchimedio (CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Colchin (KR);</li>\n      <li>Colchiquim (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Colchis (BR);</li>\n      <li>Colchisol (PE);</li>\n      <li>Colchysat Burger (DE);</li>\n      <li>Colcine (TH);</li>\n      <li>Colcitex (SG);</li>\n      <li>Colgout (AU, HK, NZ);</li>\n      <li>Colmediten (KW, QA, SA);</li>\n      <li>Coluric (BD);</li>\n      <li>Conicine (TW);</li>\n      <li>Cryscol (BD);</li>\n      <li>Gotine (QA, SA);</li>\n      <li>Goutcolcin (VN);</li>\n      <li>Goutic (TH);</li>\n      <li>Goutichine (TH);</li>\n      <li>Goutnil (IN, LK, PH);</li>\n      <li>Kolchin (BD);</li>\n      <li>Kolhikum Dyspert (UA);</li>\n      <li>Kolkisin (NO);</li>\n      <li>L-Cisin (ID);</li>\n      <li>Lengout (AU);</li>\n      <li>Lennon-Colchicine (ZA);</li>\n      <li>Oripicin (VN);</li>\n      <li>Prochic (TH);</li>\n      <li>Recolfar (ID);</li>\n      <li>Sixol (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tolchicine (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colchicine tablet [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals of New York, LLC; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colcrys (colchicine) [prescribing information]. Deerfield, IL: Takeda; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jamp-Colchicine (colchicine) [prescribing information]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Majeed HA, Carroll JE, Khuffash FA, et al, &ldquo;Long-term Colchicine Prophylaxis in Children With Familial Mediterranean Fever (Recurrent Hereditary Polyserositis),&rdquo; <i>J Pediatr</i>, 1990, 116(6):997-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/2112191/pubmed\" target=\"_blank\" id=\"2112191\">2112191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Majeed HA, Rawashdeh M, el-Shanti H, Qubain H, Khuri-Bulos N, Shahin HM. Familial Mediterranean fever in children: the expanded clinical profile. <i>QJM</i>. 1999;92(6):309-318.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/10616706/pubmed\" target=\"_blank\" id=\"10616706\">10616706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitigare (colchicine) [prescribing information]. Memphis, TN: Hikma Americas; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    pms-Colchicine [prescribing information]. Montreal, Quebec, Canada: Pharmascience Inc; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. <i>Ann Rheum Dis</i>. 2016;75(4):644-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/26802180/pubmed\" target=\"_blank\" id=\"26802180\">26802180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26899755\"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-pediatric-drug-information/abstract-text/26899755/pubmed\" target=\"_blank\" id=\"26899755\">26899755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13179 Version 140.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8108144\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13869718\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046565\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046556\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154279\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F154263\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8097684\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046568\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104450\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F154297\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046567\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F154346\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154343\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154285\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154267\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F154332\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F154272\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F154299\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154275\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10923644\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046564\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154266\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F154284\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F154287\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F154289\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13179|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">Colchicine: Drug information</a></li><li><a href=\"topic.htm?path=colchicine-patient-drug-information\" class=\"drug drug_patient\">Colchicine: Patient drug information</a></li></ul></div></div>","javascript":null}